Durand A, Thénot JP, Bianchetti G, Morselli PL (1992). "Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem". Drug Metabolism Reviews. 24 (2): 239–266. doi:10.3109/03602539208996294. PMID1576937.
Morselli PL (May 1990). "On the therapeutic action of alpidem in anxiety disorders: an overview of the European data". Pharmacopsychiatry. 23 (Suppl 3): 129–134. doi:10.1055/s-2007-1014549. PMID1974073.
Zivkovic B, Morel E, Joly D, Perrault G, Sanger DJ, Lloyd KG (May 1990). "Pharmacological and behavioral profile of alpidem as an anxiolytic". Pharmacopsychiatry. 23 (Suppl 3): 108–113. doi:10.1055/s-2007-1014545. PMID1974069. S2CID41341117.
Saletu B, Grünberger J, Linzmayer L (April 1986). "Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry". International Clinical Psychopharmacology. 1 (2): 145–164. doi:10.1097/00004850-198604000-00006. PMID2883214.
Kunovac JL, Stahl SM (December 1995). "Future directions in anxiolytic pharmacotherapy". The Psychiatric Clinics of North America. 18 (4): 895–909. doi:10.1016/S0193-953X(18)30030-3. PMID8748388.
Verster J, Veldhuijzen D, Volkerts E (1 June 2005). "Is it Safe to Drive a Car when Treated with Anxiolytics? Evidence from on-the-Road Driving Studies During Normal Traffic". Current Psychiatry Reviews. 1 (2): 215–225. doi:10.2174/1573400054065613. ISSN1573-4005.
Patat A, Perault MC, Vandel B, Danjou P, Brohier S, Zieleniuk I, Rosenzweig P (January 1995). "Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers". Journal of Psychopharmacology. 9 (2): 91–101. doi:10.1177/026988119500900203. PMID22298734. S2CID25269937.
Labbe G, Pessayre D, Fromenty B (August 2008). "Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies". Fundamental & Clinical Pharmacology. 22 (4): 335–353. doi:10.1111/j.1472-8206.2008.00608.x. PMID18705745. S2CID22969724.
Pessayre D, Mansouri A, Berson A, Fromenty B (2010). "Mitochondrial involvement in drug-induced liver injury". Adverse Drug Reactions. Handbook of Experimental Pharmacology. Vol. 196. pp. 311–365. doi:10.1007/978-3-642-00663-0_11. ISBN978-3-642-00662-3. PMID20020267.
Musch B, Morselli PL, Priore P (April 1988). "Clinical studies with the new anxiolytic alpidem in anxious patients: an overview of the European experiences". Pharmacology, Biochemistry, and Behavior. 29 (4): 803–806. doi:10.1016/0091-3057(88)90211-0. PMID2901120. S2CID42445239.
Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C (2009). "Translocator protein ligands as promising therapeutic tools for anxiety disorders". Current Medicinal Chemistry. 16 (26): 3359–3380. doi:10.2174/092986709789057653. PMID19548867.
Kozikowski AP, Ma D, Romeo E, Auta J, Papadopoulos V, Puia G, Costa E, Guidotti A (August 1992). "Synthesis of (2-Arylindol-3-yl) acetamides as Probes of Mitochondrial Steroidogenesis—A New Mechanism for GABAA Receptor Modulation". Angewandte Chemie International Edition in English. 31 (8): 1060–2. doi:10.1002/anie.199210601.
Zivkovic B, Arbilla S, Perrault G, Sanger DJ, Langer SZ (September 1991). "Alpidem, an omega-1 receptor-selective partial agonist: a new approach to anxiety treatment". European Neuropsychopharmacology. 1 (3): 202–205. doi:10.1016/0924-977X(91)90485-D. ISSN0924-977X. S2CID54414875.
Haefely W, Martin JR, Schoch P (November 1990). "Novel anxiolytics that act as partial agonists at benzodiazepine receptors". Trends in Pharmacological Sciences. 11 (11): 452–456. doi:10.1016/0165-6147(90)90126-s. PMID1980040.
Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R (January 2012). "Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile". Journal of Neuroendocrinology. 24 (1): 82–92. doi:10.1111/j.1365-2826.2011.02166.x. PMID21609361. S2CID21476596.
Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. (December 2010). "Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders". Nature Reviews. Drug Discovery. 9 (12): 971–988. doi:10.1038/nrd3295. PMID21119734. S2CID23296183.
Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994). "Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes". Neuroscience and Biobehavioral Reviews. 18 (3): 355–372. doi:10.1016/0149-7634(94)90049-3. PMID7984354. S2CID11612995.
Langer SZ, Faure-Halley C, Seeburg P, Graham D, Arbilla S (September 1992). "The selectivity of zolpidem and alpidem for the α1-subunit of the GABAA receptor". European Neuropsychopharmacology. 2 (3): 232–234. doi:10.1016/0924-977X(92)90081-I. ISSN0924-977X. S2CID140210499.
Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE (May 1990). "Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs". Pharmacopsychiatry. 23 (Suppl 3): 103–107. doi:10.1055/s-2007-1014544. PMID1974068. S2CID46448714.
Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, et al. (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology, Biochemistry, and Behavior. 213: 173321. doi:10.1016/j.pbb.2021.173321. PMID35041859. S2CID245963990.
Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1991). "Animal models of anxiety and the development of novel anxiolytic drugs". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 15 (2): 205–212. doi:10.1016/0278-5846(91)90082-c. PMID1678541. S2CID36709046.
Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (December 2000). "Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands". Psychopharmacology. 153 (1): 67–84. doi:10.1007/s002130000567. PMID11255930. S2CID1171230.
Quagliato LA, Carta MG, Nardi AE (2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID36099401. S2CID252219658.
Durand A, Thénot JP, Bianchetti G, Morselli PL (1992). "Comparative pharmacokinetic profile of two imidazopyridine drugs: zolpidem and alpidem". Drug Metabolism Reviews. 24 (2): 239–266. doi:10.3109/03602539208996294. PMID1576937.
Morselli PL (May 1990). "On the therapeutic action of alpidem in anxiety disorders: an overview of the European data". Pharmacopsychiatry. 23 (Suppl 3): 129–134. doi:10.1055/s-2007-1014549. PMID1974073.
Zivkovic B, Morel E, Joly D, Perrault G, Sanger DJ, Lloyd KG (May 1990). "Pharmacological and behavioral profile of alpidem as an anxiolytic". Pharmacopsychiatry. 23 (Suppl 3): 108–113. doi:10.1055/s-2007-1014545. PMID1974069. S2CID41341117.
Saletu B, Grünberger J, Linzmayer L (April 1986). "Pharmacokinetic and dynamic studies with a new anxiolytic imidazo-pyridine alpidem utilizing pharmaco-EEG and psychometry". International Clinical Psychopharmacology. 1 (2): 145–164. doi:10.1097/00004850-198604000-00006. PMID2883214.
Kunovac JL, Stahl SM (December 1995). "Future directions in anxiolytic pharmacotherapy". The Psychiatric Clinics of North America. 18 (4): 895–909. doi:10.1016/S0193-953X(18)30030-3. PMID8748388.
Patat A, Perault MC, Vandel B, Danjou P, Brohier S, Zieleniuk I, Rosenzweig P (January 1995). "Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers". Journal of Psychopharmacology. 9 (2): 91–101. doi:10.1177/026988119500900203. PMID22298734. S2CID25269937.
Baty V, Denis B, Goudot C, Bas V, Renkes P, Bigard MA, et al. (1994). "[Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]" [Hepatitis induced by alpidem (Ananxyl). Four cases, one of them fatal]. Gastroenterologie Clinique et Biologique (in French). 18 (12): 1129–1131. PMID7750686.
Ausset P, Malavialle P, Vallet A, Miremont G, Le Bail B, Dumas F, et al. (February 1995). "[Subfulminant hepatitis caused by alpidem and treated by liver transplantation]" [Subfulminant hepatitis caused by alpidem and treated by liver transplantation]. Gastroenterologie Clinique et Biologique (in French). 19 (2): 222–223. PMID7750714.
Labbe G, Pessayre D, Fromenty B (August 2008). "Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies". Fundamental & Clinical Pharmacology. 22 (4): 335–353. doi:10.1111/j.1472-8206.2008.00608.x. PMID18705745. S2CID22969724.
Pessayre D, Mansouri A, Berson A, Fromenty B (2010). "Mitochondrial involvement in drug-induced liver injury". Adverse Drug Reactions. Handbook of Experimental Pharmacology. Vol. 196. pp. 311–365. doi:10.1007/978-3-642-00663-0_11. ISBN978-3-642-00662-3. PMID20020267.
Berson A, Descatoire V, Sutton A, Fau D, Maulny B, Vadrot N, et al. (November 2001). "Toxicity of alpidem, a peripheral benzodiazepine receptor ligand, but not zolpidem, in rat hepatocytes: role of mitochondrial permeability transition and metabolic activation". The Journal of Pharmacology and Experimental Therapeutics. 299 (2): 793–800. PMID11602696.
Musch B, Morselli PL, Priore P (April 1988). "Clinical studies with the new anxiolytic alpidem in anxious patients: an overview of the European experiences". Pharmacology, Biochemistry, and Behavior. 29 (4): 803–806. doi:10.1016/0091-3057(88)90211-0. PMID2901120. S2CID42445239.
Taliani S, Da Settimo F, Da Pozzo E, Chelli B, Martini C (2009). "Translocator protein ligands as promising therapeutic tools for anxiety disorders". Current Medicinal Chemistry. 16 (26): 3359–3380. doi:10.2174/092986709789057653. PMID19548867.
Romeo E, Auta J, Kozikowski AP, Ma D, Papadopoulos V, Puia G, et al. (September 1992). "2-Aryl-3-indoleacetamides (FGIN-1): a new class of potent and specific ligands for the mitochondrial DBI receptor (MDR)". The Journal of Pharmacology and Experimental Therapeutics. 262 (3): 971–978. PMID1326631.
Haefely W, Martin JR, Schoch P (November 1990). "Novel anxiolytics that act as partial agonists at benzodiazepine receptors". Trends in Pharmacological Sciences. 11 (11): 452–456. doi:10.1016/0165-6147(90)90126-s. PMID1980040.
Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R (January 2012). "Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile". Journal of Neuroendocrinology. 24 (1): 82–92. doi:10.1111/j.1365-2826.2011.02166.x. PMID21609361. S2CID21476596.
Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. (December 2010). "Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders". Nature Reviews. Drug Discovery. 9 (12): 971–988. doi:10.1038/nrd3295. PMID21119734. S2CID23296183.
Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994). "Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes". Neuroscience and Biobehavioral Reviews. 18 (3): 355–372. doi:10.1016/0149-7634(94)90049-3. PMID7984354. S2CID11612995.
Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE (May 1990). "Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs". Pharmacopsychiatry. 23 (Suppl 3): 103–107. doi:10.1055/s-2007-1014544. PMID1974068. S2CID46448714.
Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, et al. (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology, Biochemistry, and Behavior. 213: 173321. doi:10.1016/j.pbb.2021.173321. PMID35041859. S2CID245963990.
Langer SZ, Arbilla S, Benavides J, Scatton B (1990). "Zolpidem and alpidem: two imidazopyridines with selectivity for omega 1- and omega 3-receptor subtypes". Advances in Biochemical Psychopharmacology. 46: 61–72. PMID1981304.
Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1991). "Animal models of anxiety and the development of novel anxiolytic drugs". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 15 (2): 205–212. doi:10.1016/0278-5846(91)90082-c. PMID1678541. S2CID36709046.
Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (December 2000). "Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands". Psychopharmacology. 153 (1): 67–84. doi:10.1007/s002130000567. PMID11255930. S2CID1171230.
Quagliato LA, Carta MG, Nardi AE (2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID36099401. S2CID252219658.
Diamond BI, Nguyen H, O'Neal E, Ochs R, Kaffeman M, Borison RL (1991). "A comparative study of alpidem, a nonbenzodiazepine, and lorazepam in patients with nonpsychotic anxiety". Psychopharmacology Bulletin. 27 (1): 67–71. PMID1677774.
Patat A, Perault MC, Vandel B, Danjou P, Brohier S, Zieleniuk I, Rosenzweig P (January 1995). "Assessment of the interaction between a partial agonist and a full agonist of benzodiazepine receptors, based on psychomotor performance and memory, in healthy volunteers". Journal of Psychopharmacology. 9 (2): 91–101. doi:10.1177/026988119500900203. PMID22298734. S2CID25269937.
Labbe G, Pessayre D, Fromenty B (August 2008). "Drug-induced liver injury through mitochondrial dysfunction: mechanisms and detection during preclinical safety studies". Fundamental & Clinical Pharmacology. 22 (4): 335–353. doi:10.1111/j.1472-8206.2008.00608.x. PMID18705745. S2CID22969724.
Musch B, Morselli PL, Priore P (April 1988). "Clinical studies with the new anxiolytic alpidem in anxious patients: an overview of the European experiences". Pharmacology, Biochemistry, and Behavior. 29 (4): 803–806. doi:10.1016/0091-3057(88)90211-0. PMID2901120. S2CID42445239.
Zivkovic B, Arbilla S, Perrault G, Sanger DJ, Langer SZ (September 1991). "Alpidem, an omega-1 receptor-selective partial agonist: a new approach to anxiety treatment". European Neuropsychopharmacology. 1 (3): 202–205. doi:10.1016/0924-977X(91)90485-D. ISSN0924-977X. S2CID54414875.
Nothdurfter C, Rammes G, Baghai TC, Schüle C, Schumacher M, Papadopoulos V, Rupprecht R (January 2012). "Translocator protein (18 kDa) as a target for novel anxiolytics with a favourable side-effect profile". Journal of Neuroendocrinology. 24 (1): 82–92. doi:10.1111/j.1365-2826.2011.02166.x. PMID21609361. S2CID21476596.
Rupprecht R, Papadopoulos V, Rammes G, Baghai TC, Fan J, Akula N, et al. (December 2010). "Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders". Nature Reviews. Drug Discovery. 9 (12): 971–988. doi:10.1038/nrd3295. PMID21119734. S2CID23296183.
Sanger DJ, Benavides J, Perrault G, Morel E, Cohen C, Joly D, Zivkovic B (1994). "Recent developments in the behavioral pharmacology of benzodiazepine (omega) receptors: evidence for the functional significance of receptor subtypes". Neuroscience and Biobehavioral Reviews. 18 (3): 355–372. doi:10.1016/0149-7634(94)90049-3. PMID7984354. S2CID11612995.
Langer SZ, Faure-Halley C, Seeburg P, Graham D, Arbilla S (September 1992). "The selectivity of zolpidem and alpidem for the α1-subunit of the GABAA receptor". European Neuropsychopharmacology. 2 (3): 232–234. doi:10.1016/0924-977X(92)90081-I. ISSN0924-977X. S2CID140210499.
Langer SZ, Arbilla S, Tan S, Lloyd KG, George P, Allen J, Wick AE (May 1990). "Selectivity for omega-receptor subtypes as a strategy for the development of anxiolytic drugs". Pharmacopsychiatry. 23 (Suppl 3): 103–107. doi:10.1055/s-2007-1014544. PMID1974068. S2CID46448714.
Witkin JM, Lippa A, Smith JL, Jin X, Ping X, Biggerstaff A, et al. (February 2022). "The imidazodiazepine, KRM-II-81: An example of a newly emerging generation of GABAkines for neurological and psychiatric disorders". Pharmacology, Biochemistry, and Behavior. 213: 173321. doi:10.1016/j.pbb.2021.173321. PMID35041859. S2CID245963990.
Sanger DJ, Perrault G, Morel E, Joly D, Zivkovic B (1991). "Animal models of anxiety and the development of novel anxiolytic drugs". Progress in Neuro-Psychopharmacology & Biological Psychiatry. 15 (2): 205–212. doi:10.1016/0278-5846(91)90082-c. PMID1678541. S2CID36709046.
Bergman J, France CP, Holtzman SG, Katz JL, Koek W, Stephens DN (December 2000). "Agonist efficacy, drug dependence, and medications development: preclinical evaluation of opioid, dopaminergic, and GABAA-ergic ligands". Psychopharmacology. 153 (1): 67–84. doi:10.1007/s002130000567. PMID11255930. S2CID1171230.
Quagliato LA, Carta MG, Nardi AE (2022). "Panic Disorder Seeks More Specific Drugs for Treatment: Might the Amygdala Be the Best Target?". Journal of Clinical Psychopharmacology. 42 (5): 427–428. doi:10.1097/JCP.0000000000001591. PMID36099401. S2CID252219658.
Verster J, Veldhuijzen D, Volkerts E (1 June 2005). "Is it Safe to Drive a Car when Treated with Anxiolytics? Evidence from on-the-Road Driving Studies During Normal Traffic". Current Psychiatry Reviews. 1 (2): 215–225. doi:10.2174/1573400054065613. ISSN1573-4005.
Zivkovic B, Arbilla S, Perrault G, Sanger DJ, Langer SZ (September 1991). "Alpidem, an omega-1 receptor-selective partial agonist: a new approach to anxiety treatment". European Neuropsychopharmacology. 1 (3): 202–205. doi:10.1016/0924-977X(91)90485-D. ISSN0924-977X. S2CID54414875.
Langer SZ, Faure-Halley C, Seeburg P, Graham D, Arbilla S (September 1992). "The selectivity of zolpidem and alpidem for the α1-subunit of the GABAA receptor". European Neuropsychopharmacology. 2 (3): 232–234. doi:10.1016/0924-977X(92)90081-I. ISSN0924-977X. S2CID140210499.
